
Novo Nordisk A/S’s diabetes drug Victoza yielded mixed results in a mid-stage study of Alzheimer’s disease, failing to meet its primary goal while showing hints that larger trials of similar drugs may be successful.
Source link
Novo Nordisk A/S’s diabetes drug Victoza yielded mixed results in a mid-stage study of Alzheimer’s disease, failing to meet its primary goal while showing hints that larger trials of similar drugs may be successful.
Source link
Vista Equity Partners has told investors it’s winding down its hedge fund amid a “structural shift” in markets toward private assets. Source link
T-Mobile US Inc. is postponing its sale of more than $500 million in asset backed securities supported by wireless equipment plans, according to people familiar with the matter. Source link